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DifferenceAbstract The purpose of this work is to evaluate the effect of sex on the outcome of congenital
heart diseases (CHDs) in children. The frequency of occurrence of each outcome within the disease
is also detected.
Methods: 312 patients (171 males and 141 females) with CHDs aged less than 12 years were
included in this study. For them complete history taking, physical examination, chest X-ray, elec-
trocardiography and echocardiography were done. The following aspects were recorded: mortality,
surgical repair, development of pulmonary hypertension, diagnosis of heart failure, hospitalization
due to chest infection and growth parameters (weight and height).
Results: Of 312 patients the most frequent two diagnoses were atrial septal defect (28.8%), and
ventricular septal defect (28.2%). Death occurred in 4.8% of patients with no signiﬁcant gender dif-
ference. 11.9% of patients were treated surgically with no sex disparity. 23.1% developed heart fail-
ure and 34.9% of the patients developed pulmonary hypertension with no signiﬁcant sex difference.
35.6% and 34.6% of the patients were below 10th percentile for weight for age and height for age,
respectively with no sex difference. Hospitalization due to chest infection occurred in 42.9% of the
patients; females had signiﬁcantly higher risk than males.
Conclusion: Females are more vulnerable to hospitalization due to chest infection than males in
children with congenital heart diseases while as regards mortality, access to surgery, occurrence
of heart failure, development of pulmonary hypertension and affection of growth, no signiﬁcant
gender differences were detected.
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Congenital heart diseases (CHDs) are responsible for the larg-
est proportion (30–50%) of mortality caused by birth defects
in pediatric age.1 Surgical repair of cardiac defect alters the
prognosis of CHDs.2 Genetic factors in regulation of the car-
diovascular system and predisposition to heart failure have
been evidenced recently.3 Pulmonary arterial hypertension
affects the course of CHDs, morbidity and mortality in many
children.4 Prolonged hospitalization due to respiratory tract
infections is more common in these patients.5 There is obvious
retardation of growth parameters among those children.6
Many factors contribute to the affection of growth among
these children as hypoxia and defective perfusion to the grow-
ing tissues, hyper metabolic state due to increased metabolic
rate and also malnutrition due to decreased appetite.7 Sex dif-
ferences in the outcome of CHDs among adults are evidenced
by Verheugt et al.,8 but there is a lack in researches that
explain if there is an impact of gender on the prognosis and
outcome of CHDs in pediatric age groups.
Material and methods
It is a prospective, cross sectional descriptive study. The study
was conducted in El Fayoum University hospital (pediatric
cardiology clinic and inpatient). The study enrolled 312
CHD patients, 171 males and 141 females. The diagnosis
was conﬁrmed by echocardiography using Vivid 3 ultrasound
machine made in Norway with a 5S MHz transducer phase
array scanner. The protocol for the research project has been
approved by the regional Ethics Committee. The work had
been carried out in accordance with The Code of Ethics of
the World Medical Association (Declaration of Helsinki) for
experiments involving humans. The parents gave informed
consent, they understood and signed it.
Inclusion criteria
Patients with CHDs aged 612 years.
Exclusion criteria
Patients with associated extracardiac malformations or genetic
disorders, children with isolated cardiac arrhythmias, cardio-
myopathy, acquired heart disease, isolated dextrocardia, car-
diac tumors and mitral valve displacement with leaﬂet
prolapse of less than 2 mm beyond the long axis annular plane
without leaﬂet thickening were excluded from the study.
Complete medical records were available for all patients,
who had been followed in the pediatric cardiology clinic of
the El-Fayoum University Hospital, Fayoum governorate,
Egypt.
All cases were classiﬁed according to the anatomical diag-
nosis. The participants had the following distribution of
pathologies: Atrial septal defect (ASD); ventricular septal
defect (VSD), patent ductus arteriorus PDA), tetralogy of fal-
lot (TOF), valvular pulmonary stenosis (VPS), transposition of
the great arteries (TGA), atrioventricular canal (AV canal);
combined ASD and VSD, total anomalous pulmonary venous
drainage (TAPVR), mitral valve prolapse (MVP) and otheranomalies which included together in one item due to low fre-
quency of them in our study population.
Work for the study started on April 2012 and ended on
August 2013. The following outcomes were studied in our
search, mortality, surgical repair, occurrence of heart failure,
development of pulmonary hypertension, hospitalization due
to chest infection and lastly affection of growth. Informed con-
sent was taken by one of the parents of each patient.
Detailed medical history and physical examination were
done with special emphasis on.
- History of any surgical cardiac procedure and the presence
of surgical scar.
- Symptoms and signs of HF, PH and chest infection. Chest
infection with respiratory distress (grade 2, 3 or 4) or oxy-
gen saturations of less than 90% is considered an indication
for hospitalization.9
- Assessment of growth by anthropometric measurements
was represented by weight and length or height. Measured
weight and height were plotted on Egyptian growth Charts
to detect weight for age and height (length) for age percen-
tiles for each patient. Less than 10th percentile for weight
or height was considered a cutoff point for poor growth
according to Program for Women, Infants, and Children
(WIC).10
The patients were subjected to:
- Chest X-ray and ECG.
- Echocardiographic evaluation of systolic pulmonary arte-
rial pressure was estimated on the basis of tricuspid regur-
gitation jet velocity measurements and/or simpliﬁed
Bernolli equation. Tricuspid regurgitation is often visual-
ized in the apical or subcostal views. The most recently
recorded pulmonary arterial pressure value was used. Pul-
monary arterial hypertension was deﬁned as a systolic pul-
monary pressure >35 mm Hg.11 For moderate sedation,
50 mg/kg of chloral hydrate was given to the patients prior
to echocardiography, if the child did not respond within
30 min after the ﬁrst dose; another half dose of the drug
as the second dose was given.12
Patients with suspicion of chest infection by clinical exam-
ination were subjected to laboratory tests (complete blood
count, C-reactive protein and sputum culture & sensitivity)
and chest X-ray to conﬁrm the diagnosis.
Statistical analysis (calculation)
Collected data were computerized and analyzed using Statisti-
cal Package for Social Science (SPSS) version 16. Descriptive
statistics were used to describe variables; percent and propor-
tion for qualitative variables. Highly variable data where
co-efﬁcient of variation (ratio of the standard deviation to
the mean) is more than 20% were presented by median and
range. Comparison between male and female groups was done
for qualitative variables using chi-Square test & ﬁsher exact
test when expected cell count was less than 5, independent
t-test and Mann–Whitney test for quantitative variables.
P-values with signiﬁcance of less than 0.05 were considered
statistically signiﬁcant.
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The study included 312 patients, 171 males and 141 females.
Males’ median age was 86 months (range, 2–140). Females’
median age was 78 months (range 3–142). Median weight per-
centile for males was 25th percentile (range, 3rd to 50th) while
for females it was 10th percentile (range, 3rd to 50th). Median
height percentile for males and females was 25th percentile
(range 3rd to 50th).
The most frequent two diagnoses were ASD (28.5% of
patients) then VSD (28.2% of patients). The diagnosis of
PDA was signiﬁcantly higher in females (P-value was 0.024)
while diagnosis of TOF was signiﬁcantly higher in males (P-va-
lue was 0.027). No signiﬁcant differences regarding distribu-
tion of other diagnoses were observed (Table 1).
Among all patients, percentage of mortality was 4.8%.
Surgical repair was performed in 11.9%. 22.8% and 32.7%
of patients developed HF and PH, respectively. The percentage
of hospitalization due to chest infection was 48.2%, it was sig-
niﬁcantly higher in females (P-value was0.04). There are no
signiﬁcant differences between males and females as regards
mortality, access to surgery, HF, PH and affection of growth
(P-value > 0.05) (Table 2).
Death occurred in 1.6%, 6.1% and 5.26% of males with
ASD, VSD and combined VSD & ASD, respectively. In fe-
males death occurred in 0%, 2.6% and 5% of patients with
ASD, VSD and combined VSD & ASD, respectively. The mor-
tality percentage was highest among patients with TAPVR
(50% in both sexes), mortality percentages among patients
with TGA were 25% for males and 33.3 for females. Death
occurred in 16.7% of females with AV canal (Table 3).
Heart failure as a complication of CHDs was signiﬁcantly
high in males with VSD (P-value was 0.001) and also in both
sexes with combined ASD & VSD. No cases of heart failure
were recorded in patients with TOF, MVP, and TGA (Table 4).
Pulmonary hypertension was signiﬁcantly high in both
sexes with TGA while no cases were recorded in patients with
TOF, MVP, and TGA (Table 5).Table 1 Distribution of patients according to diagnosis.
Diagnosis Males=171 Female
No. % No.
ASD 53 31.1 37
VSD 49 28.7 39
Combined ASD&VSD 19 11.1 20
PDA 12 7 21
TOF 11 6.4 2
PS 8 4.7 7
MVP 6 3.5 2
TGA 4 2.3 3
AV canal 3 1.8 6
TAPVR 2 1.2 2
Other diagnosesa 4 2.3 2
ASD, atrial septal defect; VSD, ventricular septal defect; PDA, patent d
stenosis; TGA, transposition of the great arteries; AV canal, atrioventricu
mitral valve prolapse.
a Other diagnoses as single ventricle, partial anomalous pulmonary venDiscussion
Our study was conducted to explore gender differences in the
outcome of CHDs among children. The overall mortality rate
was about 4.8% among all patients with no sex difference. In a
study among Danish people, the percentages of mortality
among patients with CHDs were 20% at one year of age
and 25% at 10 years of age.13 In another study by Shah
et al. the mortality rate was 20%.14 The differences between
our results and the others may be due to racial disparity, the
criteria of choosing patients or in the time range of the re-
search. Although in our society male children have more com-
pliance to medical care and follow up than female, no gender
difference in mortality was found in our study. This agrees
with a study by Verheugt et al. that conducted on adult
patients.8 In contrast, a study by Boneva et al.15 found that
higher mortality rate was in males.
In our study there is low percentage of access to surgery
among both sexes. That may be due to the absence of near
and easy access to this line of treatment as surgical interven-
tion is not performed at any hospital in our city and need refer-
ral to another city. Patients from rural areas are at risk of
delayed surgical care.16 There was no signiﬁcant gender differ-
ence as regards access to surgery in our study. However, in a
study performed on Indian children with CHDs, female gender
was considered an important determinant of non-compliance
with cardiac surgery.17
As regards occurrence of HF, no difference between males
and females was detected. In a study performed on adults, wo-
men were more likely to develop diastolic heart failure with
normal left ventricular ejection compared with men; this may
be due to small sized atrium in females. Low levels of testoster-
one in adult patients with heart failure were found and so adult
patients with older ages were more vulnerable to develop heart
failure due to reduced level of testosterone.18 Absence of these
anatomic and hormonal variations between males and females
in children may be the cause of absence of gender difference in
occurrence of heart failure among them.s=141 Total = 312 P-value
% No. %
26.5 90 28.5 0.35
27.7 88 28.2 0.84
14.2 39 12.5 0.41
14.1 33 10.6 0.024
1.4 13 4.2 0.027
5 15 4.8 0.9
1.4 8 2.9 0.3
2.1 7 2.2 0.99
4.3 9 2.8 0.18
1.4 4 1.3 >0.99
1.4 6 1.9 0.21
uctus arteriorus; TOF, tetralogy of fallot; VPS, valvular pulmonary
lar canal; TAPVR, total anomalous pulmonary venous return; MVP,
ous return, aortic coarctation and tricuspid atresia.
Table 2 Outcomes of CHD (males and females differences).
Outcomes Males Females = 141 Total P-value Odd ratio Odd ratio CI
No. % No. % No. %
Mortality 8 4.7 7 5 15 4.8 0.91 1.05 0.37–2.99
Surgical repair 20 11.8 17 12.1 37 11.9 0.9 1.028 0.516–2.014
HF 32 18.8 39 27.7 71 22.8 0.065 1.64 0.9–2.8
PH 53 31.2 49 34.8 102 32.7 0.5 1.17 0.7–1.8
Hospitalization due to chest infection 73 42.9 77 54.6 150 48.2 0.04 1.59 1.02–2.5
Weight 6 10th percentile 60 35.1 51 36.2 111 35.6 0.6 1.126 0.72–1.76
Height 6 10th percentile 56 32.7 52 36.9 108 34.6 0.46 1.18 0.75–1.85
%, percentage; CI, conﬁdence interval; HF, heart failure; PH, pulmonary hypertension.











ASD 53 1 1.9 0.47 37 0 0 1.0
VSD 49 3 6.1 0.7 39 1 2.6 0.67
Combined ASD&VSD 19 1 5.26 0.4 20 1 5 0.54
PDA 12 0 0 0.55 21 1 4.76 1.0
TOF 11 0 0 1.0 2 0 0 1.0
P.S 8 0 0 1.0 7 0 0 1.0
MVP 6 0 0 1.0 2 0 0 1.0
TGA 4 1 25 0.5 3 1 33.3 0.6
AVcanal 3 0 0 1.0 6 1 16.7 0.39
TAPVR 2 1 50 0.4 2 1 50 0.35
ASD, atrial septal defect; VSD, ventricular septal defect; PDA, patent ductus arteriorus; TOF, tetralogy of fallot; VPS, valvular pulmonary
stenosis; TGA, transposition of the great arteries; AV canal, atrioventricular canal; TAPVR, total anomalous pulmonary venous return; MVP,
mitral valve prolapse.











ASD 53 1 1.9 0.47 37 0 0 1.0
VSD 49 9 18.4 0.001 39 12 30.7 0.09
Combined ASD&VSD 19 10 52.6 0.04 20 12 60 0.03
PDA 12 5 41.7 0.5 21 8 38.1 0.15
TOF 11 0 0 1.0 2 0 0 1.0
P.S 8 0 0 1.0 7 0 0 1.0
MVP 6 0 0 1.0 2 0 0 1.0
TGA 4 3 75 0.5 3 2 66.7 0.6
AV canal 3 2 66.6 0.23 6 3 50 0.3
TAPVR 2 1 50 0.4 2 1 50 0.35
ASD, atrial septal defect; VSD, ventricular septal defect; PDA, patent ductus arteriorus; TOF, tetralogy of fallot; VPS, valvular pulmonary
stenosis; TGA, transposition of the great arteries; AV canal, atrioventricular canal; TAPVR, total anomalous pulmonary venous return; MVP,
mitral valve prolapse.
38 Z.T. Atwa, H.H. SafarNo gender difference in the development of pulmonary
hypertension was detected in our study. In contrast to these
results, females were at higher risk of pulmonary hypertension
than males in a study that conducted also on adult patients
with CHDs.8 Hormonal difference and the effect of pregnancy
in adult female may be the cause, as these factors are nearly
absent in children, no difference was detected in our study.Females had striking higher risk of hospitalization due to
chest infection than males. Reluctance of medical care and fol-
low up as regards females in our society may contribute to
deterioration of their medical condition and so more need
for hospitalization. Our result disagrees with Shah et al.14
who found that males had higher rate of hospital admission,
with male to female ratio was 1.5:1.















ASD 53 5 9.4 0.47 37 2 5.4 1.0
VSD 49 20 40.8 0.001 39 12 30.7 0.09
Combined ASD&VSD 19 15 78.9 0.04 20 14 34 0.03
PDA 12 4 33.3 0.55 21 8 38.1 1.0
TOF 11 0 0 1.0 2 0 0 1.0
P.S 8 0 0 1.0 7 0 0 1.0
MVP 6 0 0 1.0 2 0 0 1.0
TGA 4 4 100 0.03 3 3 100 0.04
AV canal 3 2 66.6 .35 6 4 66.7 0.25
TAPVR 2 1 50 0.4 2 1 50 0.035
ASD, atrial septal defect; VSD, ventricular septal defect; PDA, patent ductus arteriorus; TOF, tetralogy of fallot; VPS, valvular pulmonary
stenosis; TGA, transposition of the great arteries; AV canal, atrioventricular canal; TAPVR, total anomalous pulmonary venous return; MVP,
mitral valve prolapse.
Congenital heart diseases-sex difference 3935.6% and 34.6% of patients in our study were below 10th
percentile for weight for age and height for age respectively.
The etiology of poor growth in these children is multifactorial,
increased metabolic demand due to the cardiac defect,19 hyp-
oxemia and poor perfusion to the growing tissues, reduction
in the level of serum insulin growth factor 1(IGF-I) concentra-
tions due to the effect of chronic hypoxemia.20 No gender dif-
ference in the affection of growth was detected in our study.
However, Da Silva et al. found greater affection of weight in
boys while greater affection of height in females with congen-
ital heart diseases.21
Conclusion
In children with congenital heart diseases, females are more
vulnerable to hospitalization due to chest infection than males
while as regards mortality, access to surgery, occurrence of
heart failure, development of pulmonary hypertension and
affection of growth, no signiﬁcant gender differences were
detected.
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